Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › SNDX

Syndax Pharmaceuticals

SNDX Rare disease Lead: Approved 3 Biotech Distilled articles ↓ 24 filings & releases ↓ Cash $136M (Sep 30, 2026) ↓ 3 verdicts ↓ 7 timing quotes ↓
ImmunologyOncology ProteinSmall Molecule

Market cap $852M 89.3M shares (10-Q, Jul 31, 2026) × $9.54 close Nov 6, 2026

Most recent annual filing: 2026-02-26

Catalyst timeline

13 trackedQuarter catalyst calendar →
  1. Revuforj 2H26 revumenib readout2H 2026Revuforj 2H26 revumenib readout, 2H 2026, notable
  2. SNDX-4321 EGFR IND filingYE 2026SNDX-4321 EGFR IND filing, YE 2026, notable
  3. Revuforj 4Q26 revumenib readout4Q 2026Revuforj 4Q26 revumenib readout, 4Q 2026, material
  4. BEAT AML, SAVE, 708 intensive-chemo4Q 2026BEAT AML, SAVE, 708 intensive-chemo, 4Q 2026, material
  5. Revuforj revumenib trial start4Q 2026Revuforj revumenib trial start, 4Q 2026, routine
  6. Niktimvo cGVHD axatilimab Ph2 readout1Q 2027Niktimvo cGVHD axatilimab Ph2 readout, 1Q 2027, notable
  7. Revuforj revumenib Ph2 start1Q 2027Revuforj revumenib Ph2 start, 1Q 2027, routine
  8. SNDX-62122 next-gen menin Ph1 start2027SNDX-62122 next-gen menin Ph1 start, 2027, routine
  9. SNDX-4321 EGFR Ph1 start2027SNDX-4321 EGFR Ph1 start, 2027, routine
  10. MenTain trial start1Q 2027MenTain trial start, 1Q 2027, routine
  11. Revuforj 2H27 revumenib readout2H 2027Revuforj 2H27 revumenib readout, 2H 2027, material
  12. Niktimvo axatilimab Ph3 readoutEarly 2028Niktimvo axatilimab Ph3 readout, Early 2028, notable
  13. SNDX-4321 EGFR readoutearly 2028SNDX-4321 EGFR readout, early 2028, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (7 active programs)

Discontinued (3)

Capital (as filed)

Cash
$136M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$291M Sep 30, 2026
Long-term investments
$124M Sep 30, 2026
Operating cash flow
−$27.3M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$551M cash per the update of Nov 2, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (3)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (3 calls)

Every verdict Biotech Distilled has published on Syndax Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-09-04 Buy core Syndax Pharmaceuticals (SNDX) - Scientific Deep Dive for Revuforj, Niktimvo and Pipeline Products Two approved drugs generating $72.8M quarterly revenue with a funded balance sheet and four independent shots on goal justify a core buy, sized to the marketed franchise rather than the pipeline optionality.
  2. 2026-10-12 Buy core UPDATE: Syndax Pharmaceuticals (SNDX) - The Lung Option Expires MAXPIRe missed but was explicitly sized as an option, not the thesis; the marketed franchise and balance sheet are unchanged, so the buy is maintained.
  3. 2026-11-03 Buy core UPDATE: Syndax Pharmaceuticals (SNDX) - The Tripwire Holds Q3 Revuforj prescription growth of 13% and new-patient growth of 20% cleared the share-erosion tripwire, NPM1 revenue share rose, and Niktimvo economics improved, warranting an upgrade to accumulate at ~$13 with the marketed franchise growing double digits.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (7 quotes from 4 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (24)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Oct 12, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)